Genprex (GNPX) announced that the U.S. FDA has granted Fast Track Designation for the company’s lead drug candidate, REQORSA Immunogene Therapy, in combination with Genentech’s (RHHBY) Tecentriq in patients with extensive-stage small cell lung cancer (ES-SCLC) who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>